| Apleway (tofogliflozin) / Kowa, Takeda |
| Completed | 4 | 211 | Japan | TOFOGLIFLOZIN CSG452, Apleway, Deberza, insulin, placebo | Sanofi, Kowa Company, Ltd. | Type 2 Diabetes Mellitus | 01/16 | 10/16 | | |
| Completed | 4 | 65 | Japan | Tofogliflozin, DEBERZA, APLEWAY, GLP-1 analogue | Kowa Company, Ltd., Sanofi | Type 2 Diabetes Mellitus | 07/17 | 10/17 | | |
NCT02528019: Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors |
|
|
| Unknown status | 4 | 100 | Japan | DPP-4 inhibiotors, SGLT2 inhibitors, Glimepiride | Kurume University | Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications | 08/17 | 08/18 | | |
NCT02649465: SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD |
|
|
| Completed | 4 | 40 | Japan | Tofogliflozin, DEBERZA, Glimepiride | Kanazawa University, Kowa Company, Ltd. | Non-alcoholic Fatty Liver Disease | 12/20 | 06/21 | | |
